Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 is ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...